These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17986806)

  • 1. In vitro evaluation of dose-response curve for paclitaxel in breast cancer.
    Yoshimasu T; Oura S; Hirai I; Tamaki T; Kokawa Y; Ota F; Nakamura R; Shimizu Y; Kawago M; Hirai Y; Naito K; Kiyoi M; Tanino H; Okamura Y; Furukawa T
    Breast Cancer; 2007; 14(4):401-5. PubMed ID: 17986806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dose response curve of paclitaxel measured by histoculture drug response assay].
    Yoshimasu T; Oura S; Hirai I; Kokawa Y; Okamura Y; Furukawa T
    Gan To Kagaku Ryoho; 2005 Apr; 32(4):497-500. PubMed ID: 15853216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel].
    Maeda Y; Nishida M; Takao T; Harada K; Mori N; Tamesa T; Somura H; Tangoku A; Oka M; Konishi T
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1951-4. PubMed ID: 10560434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two cases of non-curatively resected scirrhous gastric cancer that responded well to weekly paclitaxel therapy].
    Suto R; Nakafuji Y; Mochizuki K; Oka K; Jinbo M; Chiba F; Moriuchi H; Ikeda Y; Nawata S; Zempo N; Kurata S; Nakayasu K; Esato K; Kamei T
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2119-23. PubMed ID: 14712775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
    Sakurai T; Tanino H; Oura S; Suzuma T; Yamamiti N; Yoshimasu T; Sakurai T; Naito Y
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):423-7. PubMed ID: 10740636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel].
    Yokoyama K; Tazawa Y; Suzuki I; Aoki Y; Shiramatsu K; Kobayashi J; Morishima Y; Kobayashi N; Toyoda Y; Fukada T; Horiguchi K; Yamamoto K; Nakano M; Miyazaki M
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):385-7. PubMed ID: 15791823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
    Kodera Y; Ito S; Fujiwara M; Mochizuki Y; Ohashi N; Ito Y; Nakayama G; Koike M; Yamamura Y; Nakao A
    Int J Clin Oncol; 2006 Dec; 11(6):449-53. PubMed ID: 17180513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Evaluation of Hormesis in Breast Cancer Using Histoculture Drug Response Assay.
    Aoishi Y; Yoshimasu T; Oura S; Kawago M; Hirai Y; Miyasaka M; Ohashi T; Nishimura Y
    Dose Response; 2019; 17(4):1559325819896183. PubMed ID: 31903070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
    Hoffman RM; Tanino H
    Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independence of cytotoxic drug sensitivity profiles and receptor subtype of invasive ductal breast carcinoma demonstrated by the histoculture drug response assay (HDRA).
    Kim KY; Chung BW; Yang I; Kim MB; Hoffman RM
    Anticancer Res; 2014 Dec; 34(12):7197-201. PubMed ID: 25503149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer.
    Shinden Y; Kijima Y; Hirata M; Arima H; Nakajyo A; Tanoue K; Maemura K; Natsugoe S
    Anticancer Res; 2016 Nov; 36(11):6173-6178. PubMed ID: 27793948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R; Osaki A; Toge T
    Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
    Toyokawa T; Sawada T; Muguruma K; Kim T; Kimura K; Inoue T; Yamashita Y; Yashiro M; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1637-40. PubMed ID: 17108715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
    Ueno S; Nakakuma T; Aramaki N; Shiozawa K; Iizuka M; Kurita A; Miyauchi K; Sengoku N; Kuranami M
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2471-3. PubMed ID: 20037459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
    Ohashi T; Yoshimasu T; Oura S; Kokawa Y; Kawago M; Hirai Y; Miyasaka M; Aoishi Y; Kiyoi M; Nishiguchi H; Honda M; Okamura Y
    Anticancer Res; 2015 May; 35(5):2669-74. PubMed ID: 25964544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes.
    Kimura M; Sano M; Fujimori M; Nakagomi H; Negishi T; Yanagita Y; Sato N
    Anticancer Res; 2008; 28(2B):1239-44. PubMed ID: 18505061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.